This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer
An RCT of 60 knee osteoarthritis patients found that Boswellia serrata extract (100mg Aflapin daily) reduced WOMAC pain scores by 48.8% and improved physical function scores by 49.4% at 30 days, significantly outperforming placebo (p < 0.001).
| Study | Participants | Finding | Quality |
|---|---|---|---|
A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee Sengupta K, Alluri KV, Satish AR, Mishra S, Golakoti T, Sarma KV, Dey D, Raychaudhuri SP — Arthritis Research & Therapy (2008) | 75 | 5-Loxin at 100mg and 250mg significantly reduced pain and improved function in knee OA patients at 90 days | High |
Comparative efficacy and tolerability of 5-Loxin and Aflapin against osteoarthritis of the knee Sengupta K, Krishnaraju AV, Vishal AA, Mishra A, Trimurtulu G, Sarma KV, Raychaudhuri SK, Raychaudhuri SP — International Journal of Medical Sciences (2010) | 60 | Aflapin 100mg/day showed faster and greater improvement in OA symptoms compared to 5-Loxin 100mg/day | High |
For osteoarthritis pain, 100-250mg of standardized Boswellia serrata extract (Aflapin or 5-Loxin, standardized to AKBA content) taken daily with food can provide meaningful pain relief within 1-2 weeks. Benefits continue to build over 30-90 days of consistent use.
A randomized, double-blind, placebo-controlled trial examining the efficacy of Boswellia serrata extract (5-Loxin and Aflapin) for reducing pain, stiffness, and inflammatory markers in patients with knee osteoarthritis.
Yes. Multiple RCTs demonstrate that Boswellia serrata extract significantly reduces osteoarthritis pain. One trial found a 48.8% reduction in WOMAC pain scores with Aflapin 100mg/day at 30 days vs 15.3% for placebo. Pain relief can begin within 5-7 days.
Boswellic acids, particularly AKBA (acetyl-11-keto-beta-boswellic acid), directly inhibit 5-lipoxygenase (5-LOX), an enzyme that produces inflammatory leukotrienes. Unlike NSAIDs, Boswellia does not inhibit COX-1, which may explain its better GI tolerability profile.
Look for extracts standardized to AKBA content. Aflapin (containing enriched boswellic acids) showed the fastest onset of action in head-to-head trials, while 5-Loxin (30% AKBA) has the most published data. Both are effective at 100-250mg daily.
While Boswellia showed meaningful pain reduction in OA trials, it has not been directly compared to prescription NSAIDs in large trials. It may be suitable as an adjunct or for those who cannot tolerate NSAIDs. Discuss with your doctor before replacing any prescribed medications.